Levetiracetam Tablet, Film Coated
Product Images NDC 70518-1796

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-1796). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam 500mg 70518 1796 00

Levetiracetam 500 mg film-coated tablets, quantity 30, labeled by RemedyRepack Inc. The label includes the NDC number 70518-1796-00, repackaging information, storage directions, and a QR code. Manufacturer is Camber Pharma, Inc., Piscataway, NJ.*

FDA Label Image

Levetiracetam 500mg 70518 1796 01

Levetiracetam 500 mg film-coated tablet label showing quantity of 60 tablets. The label features the brand RemedyRepack with a purple and black design. It includes NDC number 70518-1796-01, manufacturer information for Camber Pharma Inc., and storage instructions. Directions for use refer to the package insert.*

FDA Label Image

Levefig1

A bar chart comparing the percentage of patients across three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The chart illustrates patient response percentages for different dosage groups of Levetiracetam versus placebo.*

FDA Label Image

Levefig2

A bar chart showing the percentage of patients across three groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, with the levetiracetam 2000 mg/day group having the highest percentage, followed by 1000 mg/day and placebo.*

FDA Label Image

Levefig3

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Levefig4

A bar chart comparing the percentage of primates exhibiting a specific response between a placebo group (N=87) and a Levetiracetam group (N=101). The Levetiracetam group shows a higher percentage at 44.6%, while the placebo group shows 19.6%.*

FDA Label Image

Levefig5

A bar chart comparing the percent of patients showing clinical improvement between Placebo (N=64) and Levetiracetam (N=79). The chart shows Placebo at 45.2% and Levetiracetam at 72.2%, indicating a higher percent of improvement with Levetiracetam.*

FDA Label Image

Levefig6

A bar graph comparing the percent of seizure reduction between placebo and Levetiracetam groups. The placebo group (N=68) shows 45.2% reduction, while the Levetiracetam group (N=79) shows a 72.2% reduction, with an asterisk indicating statistical significance.*

FDA Label Image

Levestructure

Chemical structure of levetiracetam showing its molecular arrangement with identifiable amino and carbonyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.